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Expression of cyclin D2 is absent in 30–70% of gastric cancers. We investigated the role of promoter hypermethylation in the
transcriptional silencing of cyclin D2 in five gastric cell lines and 47 primary gastric carcinomas. CpG island methylation status of the
cyclin D2 gene was studied by methylation-specific polymerase chain reaction and bisulphite sequencing. RNA and protein expression
was analysed by reverse transcription–PCR and Western blot, respectively. Dense methylation of cyclin D2 was detected in three cell
lines (KATOIII, AGS and NCI-N87), which also lacked cyclin D2 mRNA and protein expression. Bisulphite DNA sequencing revealed
that loss of cyclin D2 expression was closely associated with the density of methylation in the promoter region. Treatment with DNA
methyltransferase inhibitor, 5-aza-20-deoxycytidine, restored the cyclin D2 expression level in methylated gastric cells. Among the 47
primary gastric cancers, cyclin D2 hypermethylation was detected in 23 (48.9%) cases. None of the 23 normal gastric biopsies from
noncancer patients showed hypermethylation. Hypermethylation was associated with loss of mRNA (Po0.001) and protein
(P¼0.006) expressions. Our study showed that cyclin D2 hypermethylation is associated with loss of cyclin D2 expression in a subset
of gastric cancers, which may suggest an alternative gastric carcinogenesis pathway in the absence of cyclin D2 expression.
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Cyclin D2 is involved in the regulation of the cell cycle at the point
of transition from G1 to DNA synthesis. In addition to its role in
cell cycle regulation, cyclin D2 is also implicated in cellular
differentiation and malignant transformation (Evron et al, 2001).
Overexpression of cyclin D2 has been reported in gastric cancer
and is shown to correlate with disease progression and poor
prognosis (Takano et al, 1999; Yu et al, 2001). On the other hand,
cyclin D2 expression is not universal in gastric cancer. We and
others have demonstrated that cyclin D2 mRNA and/or protein are
absent in 30–70% of gastric cancers (Yasogawa et al, 1998; Takano
et al, 1999, 2000). These results indicate that a subset of gastric
cancers arise from cyclin D2 independent pathway.
Recently, there is a growing body of evidence to suggest that
promoter hypermethylation is a major mechanism for the
silencing of tumour-suppressor genes (Jones and Laird, 1999;
Baylin and Herman, 2000). Cytosine methylation of CpG islands
located within the promoter region is generally associated with
delayed replication, condensed chromatin and inhibition of
transcription initiation (Baylin et al, 1998; Delgado et al, 1998;
Jones and Laird, 1999). Studies including ours indicated that
aberrant hypermethylation of 50 CpG islands is one of the crucial
mechanisms in the transcriptional silencing of multiple tumour-
related genes in gastric cancer (Lee et al, 1997; Iida et al, 2000;
Kang et al, 2000; Shin et al, 2000; Song et al, 2000; Leung et al,
2001). Recent studies suggested that cyclin D2 expression is
inhibited by the aberrant methylation of the promoter region of
the cyclin D2 gene in breast cancers as well as in Epstein–Barr
virus-positive Burkitt’s lymphoma (Sinclair et al, 1995; Evron et al,
2001; Lehmann et al, 2002). However, there is no available
information on the methylation status of the cyclin D2 gene in
gastric cancer. The aim of the current study was to examine the
methylation status of the CpG sites in the cyclin D2 promoter
region of gastric cancer by methylation-specific PCR (MSP) and
bisulphite DNA sequencing. We also correlated the expression of
cyclin D2 with cyclin D2 promoter hypermethylation in gastric
cancer.
MATERIALS AND METHODS
Cancer cell lines and tissues
The human gastric cancer cell lines KATO III, MKN45, MKN28,
AGS and NCI-N87 (N87) were obtained from Riken Cell Bank
(Tsukuba, Japan) or American Type Culture Collection (ATCC;
Rockville, MD, USA). All cell lines, except AGS, were maintained in
RPMI medium (Gibco BRL, Rockville, MD, USA) with 10% foetal
bovine serum (Gibco BRL). AGS cell line was kept in F-12K
medium (ATCC) with 10% foetal bovine serum.
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the time of surgery. There were 30 males and 17 females with a
mean age of 64.8 years (range 36–83). In addition, normal
endoscopic gastric biopsies from 23 noncancer subjects (mean age
53.3 years, range 35–77 years) were used as control. The samples
were immediately snap frozen in liquid nitrogen and stored at
 801C. The remaining tissue specimens were fixed in 10%
formalin and embedded in paraffin for routine histological
examination and immunohistochemical analysis. All patients gave
informed consent for obtaining the study specimens, and the study
protocol was approved by the ethics committee of the local
hospitals.
Reverse transcription–polymerase chain reaction
(RT–PCR)
Gastric tissue specimens were homogenised with an ultrasound
homogeniser. Total RNA was extracted by using RNA Tri Reagents
(CINNA/MRC, Cincinnati, OH, USA) according to the manufac-
turer’s protocol. Total RNA (1mg) was reverse transcribed into
cDNA by using dNTP (1mM), 5  reverse transcription buffer
(500mM Tris-HCl pH 8.3, 250mM KCl, 50mM MgCl2 and 50mM
DTT), 16U RNasin and 2.5U of AMV reverse transcriptase (Gibco
BRL). For PCR, the primer sequences were as follows: cyclin D2
(Evron et al, 2001), (sense) 50-CATGGAGCTGCTGTGCCACG-30
and (antisense) 50-CCGACCTACCTCCAGCATCC-30; and b-actin,
(forward) 50-TGACGGGGTCACCCACACTGTGCCCATCTA-30, (re-
verse) 50-CTAGAAGCATTTGCGGTGGACGATGGAGGG-30. The
reaction was performed at 951C for 1.5min, and was followed by
35 cycles of denaturating at 951C for 24s, annealing at 581C for 48s
and extension at 721C for 1min. The PCR products were separated
on 1.5% agarose gel and saved as digital images (Uvigrab; UVItec,
Cambridge, UK) (Figure 1A).
Western blot analysis
Proteins were extracted from cell pellets using Trizol Reagents
(Gibco BRL). Protein concentrations were measured by the
method of Bradford (Bio-Rad, Hercules, USA). In all, 20mgo f
protein was loaded per lane, separated by 10% SDS–polyacryla-
mide gel electrophoresis under reducing conditions, and trans-
ferred onto equilibrated polyvinylidene difluoride membrane
(Amersham Biosciences Com., UK) by electroblotting. Membranes
were blocked by 5% nonfat dry milk and then incubated with
anticyclin D2 antibody (dilution 1:1000; sc-181-G, goat polyclonal
antibodies; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
2.5h at room temperature. After secondary antibody incubation,
cyclin D2 was detected by the enhanced chemiluminescence
detection system (Amersham Biosciences Com.) (Figure 1C).
Immunohistochemistry
Expression of cyclin D2 protein was examined by avidin–biotin
complex (ABC) immunoperoxidase method as described pre-
viously (Yu et al, 2001). Sections of 5mm were cut from the
paraffin-embedded blocks, placed on charged glass slides,
deparaffinised, rehydrated, rinsed with distilled water and washed
with Tris-buffered saline (TBS). The slides were then treated with
3% hydrogen peroxide to block endogenous peroxidase activity.
After blocking with 5% normal serum for 20min, polyclonal
antibody against cyclin D2 (sc181, Santa Cruz, CA, USA) was
applied and incubated at 41C overnight. After rinsing, the
biotinylated secondary antibody and ABComplex/HRP (Dako A/S,
Denmark) were applied. Peroxidase activity was visualised by the
diaminobenzidine chromogen with 0.05% hydrogen peroxide. The
sections were then counterstained with haematoxylin, dehydrated,
cleared and mounted. Since this antibody may have minimal
crossreaction with cyclin D1, parallel paraffin-embedded sections
were used in staining for cyclin D1 immunoreactivity (Dako A/S).
In most cancer cases with cyclin D2 immunoreactivity, cyclin D1
was not detected, which suggested that the staining obtained was
because of cyclin D2 expression in these tumours.
Bisulphite modification
Genomic DNA from cell lines or frozen gastric tissues was
extracted by using the High Pure PCR Template Preparation kit
(Roche, Germany). Genomic DNA of 1mg was treated with sodium
bisulphite using the CpGenome DNA Modification Kit (Intergen,
Purchase, NY, USA) according to the manufacturer’s instructions.
After bisulphite treatment, cytosine residues are deaminated and
changed into uracil residues, but methylated cytosine remains
unmodified. Differentiation between methylated and unmethylated
sequences can then be made by amplification using specific
primers that target either the uracil or the cytosine nucleotide.
Methylation-specific PCR
PCR amplification was performed on the bisulphite-modified DNA
samples using primer sets targeting the CpG-rich region in the
cyclin D2 promoter. The methylated and unmethylated primer
sequences were based on the report by Evron and the regions of
primers were numbered from the transcriptional start site (Evron
et al, 2001): unmethylated reaction, 50-GTTATGTTATGTTTGTTG-
TATG-30 (sense,  1372 to  1350) and 50-TAAAATCCACCAACA-
CAATCA-30 (antisense,  1150 to  1170), 223-bp product;
and methylated reaction, 50-TACGTGTTAGGGTCGATCG-30
(sense,  1183 to  1165) and 50-CGAAATATCTACGCTAAACG-30
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Figure 1 (A) Expression of cyclin D2 mRNA in a panel of five gastric
cancer cell lines (KATO III, AGS, N87, MKN45 and MKN28) and five gastric
cancer tissues (T2, T4, T30, T39 and T45) by RT–PCR. A blank control
(H2O) was included in each PCR experiment ( ). mRNA for b-actin was
used as control for the integrity of RNA samples. A 100-bp marker was run
in parallel on an agarose gel. (B) Methylation-specific PCR was performed
after bisulphite modification of DNA. U indicates unmethylated cyclin D2
PCR products. M indicates methylated cyclin D2 PCR products. Three
representative samples of methylation-positive (T4, T30 and T35) and two
methylation-negative (T2 and T39) tumours are shown. DNA template-
negative control (H2O) was also included ( ). (C) Representative
examples of Western blot analysis of cyclin D2 expression. Lysates
(20mg of protein) from gastric cancer cell lines and primary gastric tumours
were immunoblotted with a cyclin D2 antibody.
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conducted in a 25ml reaction solution containing 1  PCR buffer,
0.25mM each of the deoxynucleoside triphosphates, 1mM of each
primer and 1U of Taq polymerase (AmpliTaq Gold; PE Applied
Biosystems, Foster City, CA, USA). The temperature profile for the
amplification was as follows: 12min at 951C, 35 cycles of
denaturing at 951C for 30s, 45s annealing at 521C, 60s extension
at 721C, and a final extension step of 5min at 721C. PCR products
were analysed in 2% agarose gels and stained with ethidium
bromide (Figure 1B). In vitro methylated control (positive control;
Intergen) and DNA template-negative control (H2O) were included
in each PCR. All reactions were repeated twice to ensure
consistency of results.
Bisulphite DNA sequencing
For bisulphite DNA sequencing analysis, PCR primers were
designed to amplify a CpG-rich region spanning from  1220 to
 883 from the transcriptional start site, which contains 27 CpG
sites. Primer sequences were: 50-TTTGTAAAGATAGTTTTGATT-
TAAGG-30( 1220 to  1195 forward) and 50-CCCCTACATCTAC-
TAACAAAC-30 ( 883 to  903, reverse). The PCR product was
cloned into the pCR4-TOPO
s vector using the TOPO TA
Cloning
s Kit (Gibco/Invitrogen, Carlsbad, USA). Multiple clones
(minimum of five) from each PCR product were sequenced using
the ABI Prism Dye Terminator Cycle Sequencing Kit (PE
Biosystems, Foster City, CA, USA) and the ABI Prism 310 DNA
Sequencer (PE Biosystems).
Treatment of cells with 5-aza-20-deoxycytidine (5-azaDC)
Cells were seeded at a density of 1 10
6cells 60mm
 1 dish. After
24h, cells were treated with 1, 5 or 10mM 5-azaDC (Sigma Chemical
Co., USA). The same concentration of DMSO was used as a control
for nonspecific solvent effect on cells. Total cellular RNA and
protein were isolated 3 and 5 days after addition of 5-azaDC as
described above.
Statistical analysis
The difference between the methylated and the unmethylated
groups was evaluated by w
2 test or Fisher’s exact test. A
two-sided P-value of less than 0.05 was considered statistically
significant.
RESULTS
Methylation of cyclin D2 is associated with transcriptional
silencing in gastric cancer cell lines
By using RT–PCR and Western blotting, cyclin D2 mRNA and
protein expression was found only in MKN28 but not in KATOIII,
AGS and N87 cell lines (Figure 1A, C). Notably, MKN45 had
reduced level of cyclin D2 mRNA expression but there was no
protein expression detected. A screen for cyclin D2 promoter
methylation was performed by MSP. Hypermethylation at the
CpG-rich region with no mRNA expression was detected in all
three cell lines (KATOIII, AGS, N87) as well as in MKN45
(Figure 1B), but was not detected in MKN28 with strong mRNA
and protein expression.
Next, we treated cyclin D2 methylated cell lines (KATOIII, AGS,
N87) with the methylation inhibitor 5-azaDC (Jones, 1985).
Expression of cyclin D2 was restored in all three methylated cell
lines after 3 days treatment with 5-AzaDC (Figure 2). The ability of
5-azaDC to enhance expression of cyclin D2 was more marked
when cells were treated for 5 days.
Hypermethylation leads to cyclin D2 silencing in
primary gastric tumours
Among the 47 primary gastric cancers, 23 (48.9%). had cyclin D2
methylation detected by MSP (Figure 1B). The presence of both
methylated and unmethylated bands in tumour samples reflects
heterogeneity of the tumour or may represent the inclusion of
normal tissues or infiltrating lymphocytes in tissue homogenates.
Of the 23 methylation-positive cases, 15 (65.2%) had complete loss
of cyclin D2 mRNA expression. In contrast, only three of 24
(12.5%) methylation-negative cases had lost cyclin D2 mRNA
expression. There was a strong association between the lack of
cyclin D2 mRNA expression and promoter hypermethylation
(Table 1; Po0.001). To further demonstrate that promoter
methylation of cyclin D2 is a tumour-specific phenomenon, DNA
from 23 histologically normal gastric mucosa were tested. None of
these normal samples had methylation detected by MSP (data not
shown).
Western blot was performed in 28 randomly selected cases of
gastric cancer. In total, 10 (66.7%) of the 15 cases with promoter
hypermethylation in cyclin D2 did not express the corresponding
protein. On the other hand, only two of the 13 unmethylated
tumours did not express cyclin D2 protein (P¼0.006; Table 2). In
keeping with the findings by Western blot, cyclin D2 immunor-
eactivity was detected in the cytoplasm and nucleus of gastric
cancers without methylation (Figure 3A). In methylated tumours
(Figure 3B) and in normal gastric tissues (Figure 3C), there was no
cyclin D2 immunoreactivity detected.
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Figure 2 Inhibition of methylation restored cyclin D2 expression in
cyclin D2-negative cell lines (KATO III, AGS and N87). Cell lines were
treated with 0, 1, 5 or 10mM of 5-azaDC for 3 and 5 days, respectively. The
lower figures show the levels of the cyclin D2 expression in relation to b-
actin as measured by densitometer after treatment with different doses of
5-azaDC.
Table 1 Association between cyclin D2 mRNA expression with
promoter hypermethylation in gastric cancers
Cyclin D2 mRNA
Cyclin D2 methylation Positive Negative Total
Positive 8 23
Negative 21 3 24
Total 29 18 47
Po0.001.
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pathological and molecular characteristics of gastric cancer with
cyclin D2 methylation. cyclin D2 methylation was more common in
cancer patients X60 years of age (78.3 vs 35.7%, P¼0.01; Table 3).
However, methylation in cyclin D2 was not detected in any of the
23 normal gastric biopsies including 10 patients who were X60
years, suggesting that methylation is not an age-related phenom-
enon in normal gastric epithelium. Otherwise, there was no
significant association between cyclin D2 methylation and
clinicopathological parameters of tumour including tumour
classification, lymph node status and pathological grading.
Bisulphite DNA sequencing
To verify the MSP findings and to study the extent of promoter
methylation, bisulphite DNA sequencing was performed. The CpG-
rich region of the cyclin D2 promoter between the nucleotides
 1220 and  883 was sequenced after bisulphite modification
(Figure 4). Bisulphite genomic sequencing of the representative
PCR products showed that all the cytosines at non-CpG sites were
converted to thymine. This excluded the possibility that successful
amplification was attributable to incomplete bisulphite conversion.
Moreover, the results of MSP and bisulphite sequencing were
concordant in both cell lines and primary gastric cancers,
indicating that it is appropriate to draw inferences from the
results of the MSP.
As shown in Figure 4, the CpG island exhibited extensive
methylation in the three cell lines without cyclin D2 expression
(KATOIII, AGS, N87). In contrast, there was no methylation in the
MKN28 cell lines with positive cyclin D2 expression. Notably,
the percentage of methylation ranged from 18.5 to 88.9% in the
MKN45 cell line (Figure 4). This partial methylation may explain
the low cyclin D2 mRNA expression in the MKN45 cell line as
detected by RT–PCR.
Bisulphite sequencing was also performed in seven randomly
selected gastric cancers: two with cyclin D2 expression (T2, T39),
two with low cyclin D2 expression (T8, T35) and three cyclin D2-
negative (T4, T6, T30) cancers (Figure 4). The three cases (T4, T6
and T30) that showed hypermethylation by MSP had densely
methylated alleles by bisulphite sequencing whereas the two cases
with low cyclin D2 expression (T8 and T35) had partially
methylated CpG sites. In contrast, the two tumours with strong
cyclin D2 expression (T2, T39) had virtually no methylation
detected. In addition, bisulphite sequencing of normal gastric
Figure 3 Representative immunohistochemical staining of cyclin D2. (A)
Cyclin D2 expression was detected in gastric cancers without cyclin D2
methylation. (B) In gastric cancers with promoter methylation in cyclin D2,
there was no cyclin D2 immunoreactivity detected. (C) Normal gastric
mucosa from noncancer subjects was negative for cyclin D2.
Table 2 Association between cyclin D2 protein expression and
promoter hypermethylation in human gastric cancers
Cyclin D2 protein
Cyclin D2 methylation Positive Negative Total
Positive 5 10 15
Negative 11 2 13
Total 16 12 28
P¼0.006.
Table 3 Association between cyclin D2 methylation and clinicopatho-
logical characteristics of gastric cancers
Variable Category
Total
no.
Cyclin D2
methylation (%) P-value
Sex Male 30 17 (56.7) 0.159
Female 17 6 (35.3)
Age (years) X60 23 18 (78.3) 0.01
o60 14 5 (35.7)
Lymph node metastasis Present 32 16 (50.0) 0.831
Absent 15 7 (46.7)
Depth of tumour 0.722
T1 4 2 (50.0)
T2 20 9 (45.0)
T3 11 7 (63.6)
T4 12 5 (41.7)
Lauren classification Intestinal type 16 6 (37.5) 0.429
Diffuse type 26 13 (50.0)
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region.
DISCUSSION
DNA methylation forms repressive chromatin (Brooks et al, 1996;
Bird and Wolffe, 1999; Baylin and Herman, 2000) and affects gene
expression (Baylin et al, 1998; Bird and Wolffe, 1999; Jones and
Laird, 1999). Herein, we tested the association between cyclin D2
promoter hypermethylation and loss of cyclin D2 expression in
gastric cancer. We first examined the promoter methylation status
and expression of cyclin D2 in gastric cancer cell lines. Three
gastric cancer cell lines (KATOIII, AGS and NCI-N87) with dense
methylation at the CpG islands do not express cyclin D2 mRNA
and protein. Treatment with 5-azaDC induced demethylation of
the CpG islands with reactivation of gene expression in these cyclin
D2-negative hypermethylated cell lines. The MKN28 cell line had
almost no methylation and displayed strong cyclin D2 expression.
Interestingly, the MKN45 cell line was noticed to have a reduced
level of cyclin mRNA expression, which may be related to the
partial methylation of the promoter region. The same observation
was also found in primary human gastric cancers in which the
density of methylation appears to have an inverse association
with the expression of cyclin D2. To our knowledge, this is the
first comprehensive examination of the promoter region of
cyclin D2. In keeping with our finding, Lehmann et al (2002)
reported that there was a significant increase in quantitative
changes in the methylation level from intraductal to invasive
breast cancer.
Additionally, we showed that most human gastric cancers (15
out of 23, 65.2%) with cyclin D2 promoter hypermethylation had
no cyclin D2 mRNA expression whereas the majority (21 out of 24,
87.5%) of tumours with unmethylated cyclin D2 promoter region
had cyclin D2 expression. Similar results were demonstrated in
protein level by Western blotting (Table 2). Taken together, these
results suggest that promoter hypermethylation is a major
mechanism underlying the loss of cyclin D2 function in both
gastric cell lines as well as in primary gastric cancer. Moreover, it
offers an explanation for the lack of cyclin D2 expression in a
subset of gastric cancer (Yasogawa et al, 1998; Takano et al, 1999,
2000). Intuitively, cyclin D2 expression may not be necessary in the
development of a subset of gastric cancer.
In this study, it is interesting to note that cyclin D2 is not
expressed in normal gastric tissues with unmethylated promoter.
The reason for this discrepant finding between normal and cancer
tissues may be related to the fact that cyclin D2 is a direct target of
Myc in which its expression is further controlled by b-catenin (He
et al, 1998; Bouchard et al, 1999). We and others have previously
shown that aberrant b-catenin translocation can only be observed in
gastric cancer tissues (To et al,2 0 0 1 ;T o n get al, 2001; Clements et al,
2002). Thus, it is reasonable to anticipate that cyclin D2 is absent in
normal gastric tissues with intact Wnt signalling pathway.
Promoter methylation, if involved tumour-suppressor genes
(Lee et al, 1997; Iida et al, 2000; Song et al, 2000; Leung et al, 2001),
usually results in selective growth advantage that favours the
survival of neoplastic cells. However, it is increasingly recognised
that promoter hypermethylation can also be detected in genes
other than tumour-suppressor genes. One example is the
methylation of cyclooxygenase-2 (COX-2) in gastric and colorectal
cancer (Toyota et al, 2000; Kikuchi et al, 2002). COX-2 is generally
considered to promote cancer development, and suppression of
COX-2 activity may have an antiproliferative effect on tumour.
Several groups of investigators (Toyota et al, 2000; Kikuchi et al,
2002) indicated that the promoter of COX-2 gene is methylated in a
proportion of gastric cancer but not in normal gastric tissues.
Their findings raise the possibility that a subgroup of gastric or
colorectal cancers may not be responsive to the growth inhibitory
effect of COX-2 inhibitors. In this manner, cyclin D2 over-
expression is associated with dysregulation of cell cycle and
appears to promote tumorigenesis. Promoter hypermethylation of
cyclin D2 with resultant loss of cyclin D2 may therefore have an
antineoplastic effect on gastric cancer cells. However, it is
important to recognise that cytosine methylation can also
influence tumorigenicity by mechanisms other than gene silencing.
Methylated cytosines can undergo spontaneous deamination
resulting in C-T transitions and they are also preferred targets
for G-T transversion mutations (Herman et al, 1996; Jones and
Baylin, 2002). Thus, further studies are necessary to characterise
the functional consequences of cyclin D2 methylation in the
process of gastric carcinogenesis.
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Figure 4 Bisulphite sequencing of cyclin D2 promoter region. The
nucleotide sequence from  1220 to  883 of the cyclin D2 gene is shown.
The individual CpG sites between two PCR primers are numbered
sequentially. Cytosines at the CpG site are in capitalisation. The bisulphite
sequencing PCR primers are bold and underlined whereas the MSP primers
are shown as italic. DNA from five gastric cell lines, two cyclin D2-positive
cancers (T2, T39), two cancers with low cyclin D2 expression (T8, T39)
and three cyclin D2-negative (T4, T6, T30) cancers as well as one normal
gastric tissue (N1) were bisulphite-treated, PCR-amplified and subcloned.
The sequencing results from five to eight clones for each cell line and
samples are presented. Each horizontal line represents the sequencing result
of one subclone. CpG sites within 48bp are shown as one block.
Methylated CpG sites are shown as ‘K’ whereas ‘J’ indicate unmethylated
CpG sites.
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to be a tumour-specific event since methylation was detected only
in gastric cancer and cancer cell lines, but not in normal gastric
mucosa. The detection of cyclin D2 mRNA expression in tumours
with promoter hypermethylation may be related to the extreme
sensitivity of the test, which can theoretically detect as little as
0.1% of methylated cells (Herman et al, 1996). Alternatively, a
tumour may exhibit heterogeneity in cyclin D2 methylation. In this
regard, partially methylated promoter regions may reduce the level
of transcriptional repression, resulting in partial loss of gene
expression only (Hsieh, 1994). Notably, we showed that three
cancer samples did not express cyclin D2 in the absence of
methylation. This finding suggests that alternative pathways, such
as homozygous deletion or genetic mutations, may account for loss
of cyclin D2 in some tumours. Both of these events, however, have
not been reported in gastric cancer.
Cyclin D2 methylation was more frequent in older patients,
suggesting that cyclin D2 methylation may play a more important
role in gastric carcinogenesis of elderly patients. However, we
believe that methylation in cyclin D2 is not an age-related
phenomenon since methylation is not detected in any normal
gastric mucosa including those tissues obtained from patients X60
years. Moreover, previous studies in breast cancer and Burkitt’s
lymphoma suggest that methylation in cyclin D2 is a tumour-
specific event (Sinclair et al, 1995; Evron et al, 2001; Lehmann et al,
2002).
In summary, transcriptional silencing by promoter hypermethy-
lation of the cyclin D2 gene is detected in a subset of gastric cancer.
Our results suggest that the development of a subset of gastric
cancer is independent of cyclin D2 expression. Further study is
necessary to determine the functional significance underlying the
methylation-mediated transcriptional loss of cyclin D2 in gastric
carcinogenesis.
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